Jounce Therapeutics, Inc. (JNCE): Price and Financial Metrics
JNCE Price/Volume Stats
| Current price | $1.88 | 52-week high | $5.87 |
| Prev. close | $1.93 | 52-week low | $0.58 |
| Day low | $1.88 | Volume | 11,600,600 |
| Day high | $1.93 | Avg. volume | 2,457,142 |
| 50-day MA | $1.59 | Dividend yield | N/A |
| 200-day MA | $1.99 | Market Cap | 98.95M |
JNCE Stock Price Chart Interactive Chart >
Jounce Therapeutics, Inc. (JNCE) Company Bio
Jounce Therapeutics, Inc. focuses on developing cancer immunotherapy treatments that enable the immune system to attack tumors. The company in 2012 and is based in Cambridge, Massachusetts.
Latest JNCE News From Around the Web
Below are the latest news stories about JOUNCE THERAPEUTICS INC that investors may wish to consider to help them evaluate JNCE as an investment opportunity.
United Therapeutics (UTHR) Q1 Earnings Beat, Sales MissUnited Therapeutics' (UTHR) first-quarter 2023 earnings beat estimates while sales miss the same. Tyvaso sales continue to drive the company's top line. |
Jounce Therapeutics Announces Closing of Tender OfferStockholders to Receive $1.85 Per Share in Cash Plus Contingent Value RightsCAMBRIDGE, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE) (“Jounce” or the “Company”), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that Concentra Biosciences, LLC (“Concentra”), through its wholly owned subsidiary Concentra Merger Sub, Inc. (“Concentra Merger Sub”), has successfully completed |
The past five years for Jounce Therapeutics (NASDAQ:JNCE) investors has not been profitableIt is a pleasure to report that the Jounce Therapeutics, Inc. ( NASDAQ:JNCE ) is up 67% in the last quarter. But will... |
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce TherapeuticsCatalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics are part of the Zacks Industry Outlook article. |
5 Stocks to Buy as the Drug Industry Rebounds in 2023Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one's portfolio. |
JNCE Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | -1.57% |
| 3-year | -78.59% |
| 5-year | -66.25% |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | -86.71% |
| 2021 | 19.29% |
| 2020 | -19.82% |
| 2019 | 159.05% |
Continue Researching JNCE
Want to see what other sources are saying about Jounce Therapeutics Inc's financials and stock price? Try the links below:Jounce Therapeutics Inc (JNCE) Stock Price | Nasdaq
Jounce Therapeutics Inc (JNCE) Stock Quote, History and News - Yahoo Finance
Jounce Therapeutics Inc (JNCE) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...